[ad_1]
Optimistic news emerged from AstraZeneca on Friday, with new clinical data suggesting that its COVID-19 antibody drug saw a significant reduction in severe symptomatic COVID-19 infections in recipients.
Observed in phase three clinical trials, the results saw a 77% reduction in the risk of developing symptomatic COVID-19 infection compared to the group that received a placebo.
This study examined immunity cultivated with a dose of AstraZeneca’s AZD7442, also called PROVENT, which is a combination of two antibodies that work to cultivate immunity against COVID-19.
Among the randomized trials, no patient who received the antibody cocktail developed a serious infection with COVID-19 that resulted in hospitalization. In the alternative group that received a placebo, there were three recorded cases of severe COVID-19, two of which resulted in death.
STUDY INDICATES NEW LAMBDA VARIANT MAY BE VACCINE RESISTANT
AMERICAN “ARCHBISHOP” DISTRIBUTES BLEACH AS “MIRACLE CURE” FOR COVID-19
THE SIGNS YOU HAVE THE DELTA VARIANT ARE DIFFERENT FROM THE ORIGINAL COVID-19
EVIDENCE SHOWS THE DELTA VARIANT IS DANGEROUS FOR CHILDREN
“PROVENT data shows that a dose of AZD7442, delivered in a convenient intramuscular form, can quickly and effectively prevent symptomatic COVID-19,” said Myron Levin, professor of pediatrics and medicine at the University of Colorado, who helped conduct the trials. . “With these exciting results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to resume normal life.”
Our country is in a historic fight against the Coronavirus. Add Change America to your Facebook Where Twitter feed to stay up to date with the latest news.
The drug is not technically a vaccine, but is still designed to trigger an immune response against COVID-19 and provide long-lasting protection against the virus. The two long-acting antibodies, called LAAB, are tixagevimab and cilgavimab, both of which are derived from the recovering plasma of the COVID-19 patient.
LAABs were derived by researchers at Vanderbilt and sold to AstraZeneca in June 2020.
Mene Pangalos, executive vice president of AstraZeneca, said PROVENT is believed to work as a supplement to COVID-19 vaccines for those who may not be “adequately protected”.
“We are very encouraged by these efficacy and safety data in people at high risk, showing that our long-acting antibody combination has the potential to protect against symptomatic and serious illnesses, alongside vaccines,” said she declared in the press release.
More than 75 percent of the cohort participants had some form of comorbidity that could complicate a potential COVID-19 infection. Study participants received a dose of 300 milligrams as a single intramuscular injection.
Complete PROVENT data results will be subject to peer review.
Several studies have shown that AstraZeneca’s COVID-19 vaccine decreased in effectiveness against the delta variant, as well as the Pfizer and Moderna vaccines. Since then, the Biden administration has officially launched a new rollout of boosters to help cultivate long-standing immunity in a bid to emerge from the pandemic.
“THE WAR HAS CHANGED”: CDC DOCUMENT WARNS DELTA VARIANT MORE SERIOUS THAN PREVIOUSLY THOUGHT
WHAT YOU SHOULD KNOW ABOUT THE LAMBDA CORONAVIRUS VARIANT
SOME AMERICANS GET VACCINATED IN SECRET BECAUSE THEY FEAR THE RETURN
BIDEN CALLS $ 100 PAYMENTS FOR AMERICANS TO GET VACCINATED
[ad_2]
Source link